Home
Market NewsLLY.US slimming drug is now on sale at the US Pharmacy and is expected to reach $2 billion next year.
Market NewsLLY.US slimming drug is now on sale at the US Pharmacy and is expected to reach $2 billion next year.LLY.US slimming drug is now on sale at the US Pharmacy and is expected to reach $2 billion next year.
阿思達克 12-06 01:22
LLY.US said on Tuesday that its recently approved obesity drug, Zepbound, is now on sale in US pharmacies and could cost as much as $550a month for customers who are not covered by health insurance.
Zepbound has been added to the US reimbursement preferred drug list by Express Scripts of at least one major drug benefit management company (PBM) Cigna (CI.US) and will be added to Cigna's commercial prescription list on December 15, Lilly said.
Another large PBM, Caremark, a unit of CVS Health (CVS.US), said it was still reviewing Zepbound to ensure its clinical applicability and cost-effectiveness. Optum Rx, a unit of United Health (UNH.US), did not respond.
Zepbound is the latest addition to the fast-growing market for weight-loss drugs, which is expected to grow to about $100 billion by the end of the century. Later trials have shown that Zepbound can help patients lose an average of 20% of their weight.
The market expects Zepbound sales to reach about $2 billion by 2024 and Novo Nord's rival obesity drug Wegovy to reach about $7.5 billion. As for PFE.US (Pfizer) last week, it gave up pushing its much-anticipated oral obesity drug, danuglipron, into later clinical trials.
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
More Content
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
